Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) has shared an announcement.
Shanghai Fosun Pharmaceutical announced the approval for drug registration of one of its subsidiaries, which marks a significant milestone in its operational capabilities. This approval is expected to enhance the company’s market position and could have positive implications for its stakeholders, reflecting the company’s ongoing commitment to expanding its pharmaceutical offerings.
The most recent analyst rating on (HK:2196) stock is a Sell with a HK$26.50 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, focusing on the pharmaceutical industry. It is listed on the Stock Exchange of Hong Kong and is involved in the development, manufacturing, and distribution of pharmaceutical products.
Average Trading Volume: 10,767,897
Technical Sentiment Signal: Buy
Current Market Cap: HK$79.78B
Learn more about 2196 stock on TipRanks’ Stock Analysis page.